A digital health application (DiGA) has been shown to relieve the distress that patients can experience when managing diabetes, which can compromise their care, in a rando
Roche has bolstered its R&D pipeline in oncology and neuroscience with a pair of partnerships with Orionis Biosciences and PeptiDream, parting with upfront cash of $87
The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi.
Just weeks after wagering $310 million upfront on the rights to Alnylam's hypertension therapy zilebesiran on the strength of phase 1 data, Roche has been rewarded by a po